


CTO Current Technique and Approaches



Professor Scott Harding
Department of Cardiology
Wellington Hospital

Doing the basics right is key

- Patient selection
- Avoid ad-hoc procedures
- Routine dual injections
- Careful analysis of the angiogram
- Routine use of microcatheters
- Have the equipment you need to succeed
- Have the equipment you need to deal with complications





Antegrade wire escalation remains the most commonly used strategy




Authors	Acronym	Study Period	Cases	AWE first strategy	AWE Final Success Strategy
Konstantinidis et al. ⁸⁹	EURO-CTO registry	2008-2015	17,626	64.6%	—
Tajti et al. ⁶⁰	PROGRESS-CTO	2012–2017	3,055	75%	52%
Suzuki et al. ³¹	Japanese CTO-PCI Expert Registry	2014–2015	2,846	72%	56%
Maeremans et al. ⁶¹	RECHARGE	2014–2015	1,253	77%	58%
Sapontis et al. ³	OPEN-CTO	2013–2017	1,000	55%	40.8%

The Hybrid Algorithm






Consider stopping if >3 hours, 3.7 x eGFR ml contrast, Air Kerma > 5 Gy unless procedure well advanced



Consider stopping if >3 hours, 3.7 x eGFR ml contrast, Air Kerma > 5 Gy unless procedure well advanced



The Hybrid Algorithm for Treating Chronic Total Occlusions in Europe

The RECHARGE Registry

Joren Maeremans, MSc,^{a,b} Simon Walsh, MD,^c Paul Knaapen, MD, PhD,^d James C. Spratt, MD,^e Alexandre Avran, MD,^f
Colm G. Hanratty, MD,^c Benjamin Faurie, MD, PhD,^g Pierfrancesco Agostoni, MD,^{h,i} Erwan Bressollette, MD,^j
Peter Kayaert, MD,^k Alan J. Bagnall, MD, PhD,^{l,m} Mohaned Egred, MD,^{l,m} Dave Smith, MD,ⁿ
Alexander Chase, MD, PhD,ⁿ Margaret B. McEntegart, MD, PhD,^o William H.T. Smith, MB, BChir, PhD,^p
Alun Harcombe, MD,^p Paul Kelly, MD,^q John Irving, MD,^r Elliot J. Smith, MD,^s Julian W. Strange, MD,^t
Joseph Dens, MD, PhD^{a,b}

Lesion Length ≥ 20 mm in 59%

AWE was the primary strategy in 77%!

Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry☆

Georgios Christopoulos^a, Dimitri Karpaliotis^b, Khaldoon Alaswad^c, Robert W. Yeh^{d,m}, Farouc A. Jaffer^e, R. Michael Wyman^e, William L. Lombardi^f, Rohan V. Menon^a, J. Aaron Grantham^g, David E. Kandzari^h, Nicholas Lembo^h, Jeffrey W. Moses^b, Ajay J. Kirtane^b, Manish Parikh^b, Philip Green^b, Matthew Finn^b, Santiago Garcia^{i,n}, Anthony Doing^j, Mitul Patel^{k,o}, John Bahadorani^{k,o}, Muhammad Nauman J. Tarar^a, Georgios E. Christakopoulos^a, Craig A. Thompson^l, Subhash Banerjee^a, Emmanouil S. Brilakis^{a,*}

Lesion Length was ≥ 20 mm in 75%


AWE was the primary strategy in 66%!

Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty


A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures)

Mean lesion Length was 29.1 ± 23.8 mm
AWE was the primary strategy in 54.7%

Failure of AWE is linked to lesion complexity




Patient number	329	65	82	92	63	24
	165	26	48	46	33	10



Patient number	494	91	130	138	135
----------------	-----	----	-----	-----	-----

Crossing Strategy Success by J-CTO Score


UK Hybrid Registry



As complexity increases use of dissection re-entry (antegrade *or* retrograde) techniques increases

Retrograde use and success rates

European CTO Registry





Frequency and success of Retrograde approach




	APCTO	Japanese Expert	PROGRESS	RECHARGE	OPEN CTO
	N=447	N=2596	N=1036	N=1253	N=1000
Retrograde attempted	48%	46%	42%	34%	-
Retrograde successful strategy	42%	33	26%	21%	35%
% retrograde success	86.4%	72%	63%	67%	-
ADR attempted	2%	3%*	36%	23%	-
ADR successful strategy	-	2%	26%	15%	24.3%
% ADR success	-	78%	72%	66%	-
Contrast dose (ml)	250 (200-320)	231 ± 106	260 (200–360)	250 (180-340)	262 ± 140
Fluoroscopy time (min)	48 (29-73)	-	44 (27–72)	35 (21-55)	50 ± 34
Procedure time (min)	100 (60-140)	160 ± 90	119 (82–175)	90 (60-120)	120 ± 64
Technical success rate	95%	90%	91%	86%	86%

*This represents IVUS guided wire re-entry

Use of Retrograde strategies




Why do we need ADR?



Retrograde channels are not always available and can't always be crossed

Growing evidence base for ADR

Antegrade procedures, technical success, procedural success and MACE according to use of AWE or ADR




458 ADR procedure in
1313 CTO PCIs performed
at 11 US centers

*MACE = In-hospital
death, MI, urgent repeat
TVR, tamponade or CVA

Antegrade Dissection and Reentry as Part of the Hybrid Chronic Total Occlusion Revascularization Strategy


A Subanalysis of the RECHARGE Registry (Registry of CrossBoss and Hybrid Procedures in France, the Netherlands, Belgium and United Kingdom)



Joren Maeremans, Jo Dens , James C. Spratt, Alan J. Bagnall, Wynand Stuijzand, Alexander Nap, Pierfrancesco Agostoni, William Wilson, Colm G. Hanratty, Simon Wilson, Benjamin Faurie, Alexandre Avran, Erwan Bressollette, Mohaned Egred, Paul Knaapen, Simon Walsh, and on behalf of the RECHARGE Investigators, Dave Smith, Alexander Chase, ... [Show all Authors](#) 



In Hospital ADR-associated major events occurred in 3.4% (n=10/292).

One-Year Outcomes After Successful Chronic Total Occlusion Percutaneous Coronary Intervention: The Impact of Dissection Re-Entry Techniques

W. M. Wilson,¹ MBBS, FRACP , S.J. Walsh,² MD, FRCP, A. Bagnall,^{3,4} MBCHB, PhD, FRCP, A.T. Yan,⁵ MD, FRCPC, C.G. Hanratty,² MD, FRCPI, M. Egred,^{3,4} BSC (HONS), MBCHB, MD, FRCP, E. Smith,⁶ BSC, MBBS, MD, K.G. Oldroyd,⁷ MBCHB, MD (HONS), FRCP, M. McEntegart,⁷ MD, PhD, J. Irving,⁸ MBCHB, MD, FRCPEDIN, H. Douglas,² MB, BCH, J. Strange,⁹ MBCHB, MRCP, MD, and J.C. Spratt,^{10*} BSC, MBCHB, MD, FRCP



Dissection & Re-entry: 12 month outcomes

TABLE VI. Multivariate Analysis (Cox Regression Models)


Variable	Model 1		Model 2		Model 3		Model 4	
	Odds ratio	<i>P</i> value	Odds ratio	<i>P</i> value	Odds ratio	<i>P</i> value	Odds ratio	<i>P</i> value
Final Approach								
AWE	1							
ADR	0.66 (0.3–1.5)	0.32						
RWE	0.68 (0.16–2.9)	0.61						
RDR	1.1 (0.53–2.2)	0.83						
DART (any)			0.74 (0.4–1.4)	0.35				
ADR (any)					0.67 (0.35–1.3)	0.23		
RDR (any)							1.3 (0.67–2.4)	0.47
Lesion length >25 mm	2.5 (1.3–4.8)	0.007	2.9 (1.5–5.6)	0.002	2.6 (1.5–4.8)	0.001	2.3 (1.2–4.3)	0.01
Stent length >50 mm	0.85 (0.4–1.8)	0.85	0.85 (0.4–1.7)	0.65	0.85 (0.41–1.7)	0.66	0.79 (0.39–1.6)	0.52
Disease distal (moderate or severe)	1.6 (0.82–2.9)	0.17	1.67 (0.85–3)	0.15	1.6 (0.83–3.0)	0.17	1.6 (0.86–3.1)	0.16
Bifurcation	1.2 (0.8–2.2)	0.36	1.3 (0.8–2.2)	0.3	1.3 (0.7–2.2)	0.36	1.3 (0.8–2.2)	0.34
Diabetes	1.4 (0.8–2.4)	0.3	1.4 (0.8–2.4)	0.28	1.4 (0.8–2.4)	0.18	1.3 (0.8–2.4)	0.31
In-stent restenosis	1.5 (0.6–3.6)	0.4	1.3 (0.6–3.1)	0.64	1.4 (0.6–3.3)	0.23	1.4 (0.6–3.5)	0.47

Presented as Hazard ratio (95% confidence interval) and *P* value.

AWE: Antegrade wire escalation; ADR: Antegrade dissection re-entry; RWE: retrograde wire escalation; RDR: retrograde dissection re-entry; DART: dissection and re-entry.

Complications with various techniques


FIGURE 4 In-Hospital Major Complications Classified According to Final Successful Crossing Strategy




Use of the retrograde approach was associated with higher overall in-hospital major adverse cardiac events (MACE) and risk for perforation. ADR = antegrade dissection and re-entry; AWE = antegrade wire escalation; CABG = coronary artery bypass graft; MI = myocardial infarction; PCI = percutaneous coronary intervention.

>3000 patients from PROGRESS Registry

Complications with various techniques



We should avoid uncontrolled or wire based ADR



Contemporary approach to ADR




	Classic ADR 2011	Contemporary ADR 2018
Set up	8Fr Femoral with supportive guides AL0.75/EBU 3.5	Compatible with radial access 7Fr with 7F Trapliner or 6Fr without guide extension
Initial Microcatheter	CrossBoss	Start with wire and microcatheter Finish with CrossBoss to limit dissection in re-entry zone
Re-entry catheter	Stingray	Stingray LP
Re-entry wire	Stingray wire	Stingray /Astato 20/Hornet 14/ GAIA 3 rd Next
Re-entry Technique	Stick and go	Stick and swap with Pilot 200
Hematoma Management	STRAW- if loss of visualization of distal vessel	Active management with Trapliner upfront and preemptive STRAW

Frequency and success of ADR




	APCTO	Japanese Expert	PROGRESS	RECHARGE	OPEN CTO
	N=447	N=2596	N=1036	N=1253	N=1000
Retrograde attempted	48%	46%	42%	34%	-
Retrograde successful strategy	42%	33	26%	21%	35%
% retrograde success	86.4%	72%	63%	67%	-
ADR attempted	2%	3%*	36%	23%	-
ADR successful strategy	-	2%	26%	15%	24.3%
% ADR success	-	78%	72%	66%	-
Contrast dose (ml)	250 (200-320)	231 ± 106	260 (200–360)	250 (180-340)	262 ± 140
Fluoroscopy time (min)	48 (29-73)	-	44 (27–72)	35 (21-55)	50 ± 34
Procedure time (min)	100 (60-140)	160 ± 90	119 (82–175)	90 (60-120)	120 ± 64
Technical success rate	95%	90%	91%	86%	86%

*This represents IVUS guided wire re-entry



Consider stopping if >3 hours, 3.7 x eGFR ml contrast, Air Kerma > 5 Gy unless procedure well advanced

Parallel wiring use and success in Japanese expert registry



Parallel wiring vs Stingray

Major features favouring use of stingray

- Vessel course ambiguity
- If wire subintimal at the proximal cap
- Good distal landing zone

Major features favouring use of parallel wiring

- Diffuse disease and calcification of the distal vessel
- CTO course is unambiguous
- Stingray not available or financial restraints

Global Consensus Statement



1	The principal indication for CTO-PCI is to improve symptoms
2	Dual coronary angiography and thorough, structured angiographic review should be performed in every case
3	Use of a microcatheter is essential for guidewire support
4	There are 4 CTO crossing strategies: antegrade wire escalation, antegrade dissection/re-entry, retrograde wire escalation, and retrograde dissection/re-entry
5	Change of equipment and technique increases the likelihood of success and improves the efficiency of the procedure
6	Centers and physicians performing CTO-PCI should have the necessary equipment, expertise and experience to optimize success and minimize and manage complications
7	Every effort should be made to optimize stent deployment in CTO PCI, including the frequent use of intravascular imaging

Conclusions



- Antegrade wiring, antegrade dissection and re-entry and the retrograde approach are all complementary and necessary crossing strategies.
- Antegrade wiring is the most common initial technique, while retrograde and antegrade dissection and re-entry are often required for more complex CTOs.
- There is an increasing body of data demonstrating the safety and effectiveness of targeted ADR with the Stingray system
- Wire based ADR strategies should be avoided as they are associated with higher in-hospital and long-term outcomes